SEC filing · 8-K

Heron Therapeutics, Inc.: Material agreement

Heron Therapeutics entered into a multi-product development and license agreement with Long Grove Pharmaceuticals and Capstone Development Services.

Filed September 29, 2026

Positive for the company

What happened

On September 23, 2026, Heron Therapeutics entered into a development and license agreement with Long Grove Pharmaceuticals and Capstone Development Services.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Heron Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.